Morgan joined Regulus Therapeutics in 2020, bringing 10 years of experience in drug discovery and leading translational research teams. He was previously a senior investigator at Novartis, where he established and led preclinical efforts in areas including post-myocardial infarction and heart failure, congenital heart disease, and cellular senescence. He also served as assistant professor of genetics and development biology at the University of Connecticut School of Medicine and Stem Cell Institute, where his research laboratory focused on biological aging and tissue regeneration to drive the discovery of novel mechanisms and therapeutics for treating musculoskeletal degenerative disease.  Morgan earned his B.S. in biology from Elon University, an M.S. in comparative pathology/virology from University of California, Davis, a joint Ph.D. in bioengineering from University of California, San Francisco and Berkeley, and was a postdoctoral research fellow at Children’s Hospital of Oakland Research Institute and University of California, Berkeley.